High-resolution meta-omics have enabled the discovery of the microbial enzymes that inactivate an ulcerative colitis drug and predict subsequent treatment failure, an approach that could enable more personalized treatment of inflammatory bowel disease.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cevallos, S. A. et al. mBio 12, e03227–20 (2021).
Mehta, R. S. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02217-7 (2023).
Truelove, S. C. Scand. J. Gastroenterol. Suppl. 148, 3–6 (1988).
Chriswell, M. E. et al. CSci. Transl. Med. 14, eabn5166 (2022).
Azad Khan, A. K., Piris, J. & Truelove, S. C. Lancet 2, 892–895 (1977).
Singh, S., Feuerstein, J. D., Binion, D. G. & Tremaine, W. J. Gastroenterology 156, 769–808 (2019).
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R. & Goodman, A. L. Nature 570, 462–467 (2019).
Delomenie, C. et al. J. Bacteriol. 183, 3417–3427 (2001).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Macpherson, A.J., Sauer, U. Secrets of microbiota drug metabolism. Nat Med 29, 537–538 (2023). https://doi.org/10.1038/s41591-023-02227-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-023-02227-5